Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858

Inflammation and cancer

Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111 · see citing works

Myeloid-derived-suppressor cells as regulators of the immune system

Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · see citing works

Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock

Vogl, T., Tenbrock, K., Ludwig, S., Leukert, N., Ehrhardt, C., van Zoelen, M. A. D., Nacken, W., Foell, D., van der Poll, T., Sorg, C., et al. (2007) · Nature Medicine · doi:10.1038/nm1638 · Cited by 1,418 · see citing works

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319 · see citing works

Gamma-H2AX - a novel biomarker for DNA double-strand breaks.

Kuo, L. J., & Yang, L. (2008) · PubMed · Cited by 1,173 · see citing works

History of myeloid-derived suppressor cells

Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148 · see citing works

Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia

Raaijmakers, M. H. G. P., Mukherjee, S., Guo, S., Zhang, S., Kobayashi, T., Schoonmaker, J. A., Ebert, B. L., Al-Shahrour, F., Hasserjian, R. P., Scadden, E. O., et al. (2010) · Nature · doi:10.1038/nature08851 · Cited by 1,115 · see citing works

Efficacy of Lenalidomide in Myelodysplastic Syndromes

List, A., Kurtin, S., Roe, D. J., Buresh, A., Mahadevan, D., Fuchs, D., Rimsza, L., Heaton, R., Knight, R., & Zeldis, J. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041668 · Cited by 880 · see citing works

The endogenous Toll–like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer

Ehrchen, J. M., Sunderkötter, C. H., Foell, D., Vogl, T., & Roth, J. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.1008647 · Cited by 848 · see citing works

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

Hills, R. K., Castaigné, S., Appelbaum, F. R., Delaunay, J., Petersdorf, S. H., Othus, M. K. D., Estey, E. H., Dombret, H., Chevret, S., Ifrah, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70281-5 · Cited by 722 · see citing works

The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype

Basiorka, A. A., McGraw, K. L., Eksioglu, E. A., Chen, X., Johnson, J., Zhang, L., Zhang, Q., Irvine, B. A., Cluzeau, T., Sallman, D. A., et al. (2016) · Blood · doi:10.1182/blood-2016-07-730556 · Cited by 356 · see citing works

Role Of Immature Myeloid Cells in Mechanisms of Immune Evasion In Cancer

Kusmartsev, S. A., & Gabrilovich, D. I. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0048-z · Cited by 346 · see citing works

Myelodysplastic syndromes

Nimer, S. D. (2008) · Blood · doi:10.1182/blood-2007-08-078139 · Cited by 337 · see citing works

Induction of myelodysplasia by myeloid-derived suppressor cells

Chen, X., Eksioglu, E. A., Zhou, J., Zhang, L., Djeu, J., Fortenbery, N., Epling-Burnette, P., Van Bijnen, S., Dolstra, H., Cannon, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67580 · Cited by 316 · see citing works

Tumor Necrosis Factor-α Blocks Differentiation and Enhances Suppressive Activity of Immature Myeloid Cells during Chronic Inflammation

Sade-Feldman, M., Kanterman, J., Ish‐Shalom, E., Elnekave, M., Horwitz, E. P., & Baniyash, M. (2013) · Immunity · doi:10.1016/j.immuni.2013.02.007 · Cited by 306 · see citing works

Chronic Immune Stimulation Might Act As a Trigger for the Development of Acute Myeloid Leukemia or Myelodysplastic Syndromes

Kristinsson, S. Y., Björkholm, M., Hultcrantz, M. L., Derolf, Å. R., Landgren, O., & Goldin, L. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.8540 · Cited by 288 · see citing works

Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients

Estey, E. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2731 · Cited by 235 · see citing works

Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors

Epling‐Burnette, P. K., Bai, F., Painter, J. S., Rollison, D. E. M., Salih, H. R., Krusch, M., Zou, J., Ku, E., Zhong, B., Boulware, D. C., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035519 · Cited by 232 · see citing works

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)

Larson, R. A., Boogaerts, M. A., Estey, E. H., Karanes, C., Stadtmauer, E. A., Sievers, E. L., Mineur, P., Bennett, J. M., Berger, M. S., Eten, C. B., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402677 · Cited by 221 · see citing works

Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2

Paul, S. P., Taylor, L. S., Stansbury, E. K., & McVicar, D. W. (2000) · Blood · doi:10.1182/blood.v96.2.483 · Cited by 204 · see citing works

Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2

Paul, S. P., Taylor, L. S., Stansbury, E. K., & McVicar, D. W. (2000) · Blood · doi:10.1182/blood.v96.2.483.014k40_483_490 · Cited by 202 · see citing works

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

Sheng, W., Chen, X., Rocha, K., Epling‐Burnette, P. K., Djeu, J. Y., Liu, Q., Byrd, J. C., Sokol, L., Lawrence, N., Pireddu, R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811267106 · Cited by 192 · see citing works

The Myeloid-specific Sialic Acid-binding Receptor, CD33, Associates with the Protein-tyrosine Phosphatases, SHP-1 and SHP-2

Taylor, V., Buckley, C. D., Douglas, M., Cody, A. J., Simmons, D. L., & Freeman, S. D. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.11505 · Cited by 186 · see citing works

Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma

Kapanadze, T. G., Gamrekelashvili, J., Ma, C., Chan, C., Zhao, F., Hewitt, S. M., Zender, L., Kapoor, V., Felsher, D. W., Manns, M. P., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.06.010 · Cited by 184 · see citing works

Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions

Zhou, J., Wu, J., Chen, X., Fortenbery, N. R., Eksioglu, E. A., Kodumudi, K. N., Epling-Burnette, P. K., Dong, J., Djeu, J. Y., & Sheng, W. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.01.007 · Cited by 167 · see citing works

Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug

Rowe, J. M., & Löwenberg, B. (2013) · Blood · doi:10.1182/blood-2013-03-490482 · Cited by 143 · see citing works

Transcription factor networks in B-cell differentiation link development to acute lymphoid leukemia

Somasundaram, R., Prasad, M. A. J., Ungerbäck, J., & Sigvardsson, M. (2015) · Blood · doi:10.1182/blood-2014-12-575688 · Cited by 135 · see citing works

Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts

Vasu, S., He, S., Cheney, C., Gopalakrishnan, B., Mani, R., Lozanski, G., Mo, X., Groh, V., Whitman, S. P., Konopitzky, R., et al. (2016) · Blood · doi:10.1182/blood-2015-11-680546 · Cited by 93 · see citing works

Biological Significance of Proliferation, Apoptosis, Cytokines, and Monocyte/Macrophage Cells in Bone Marrow Biopsies of 145 Patients With Myelodysplastic Syndrome

Allampallam, K., Shetty, V. T., Mundle, S. D., Dutt, D., Kravitz, H. M., Reddy, P. L., Alvi, S., Galili, N., Saberwal, G. S., Anthwal, S., et al. (2002) · International Journal of Hematology · doi:10.1007/bf02982044 · Cited by 88 · see citing works

Myelodysplastic syndromes: revisiting the role of the bone marrow microenvironment in disease pathogenesis

Raaijmakers, M. H. G. P. (2012) · International Journal of Hematology · doi:10.1007/s12185-011-1001-x · Cited by 71 · see citing works

S100A8 and S100A9 in inflammatory diseases

Roth, J., Goebeler, M., & Sorg, C. (2001) · The Lancet · doi:10.1016/s0140-6736(05)71610-x · Cited by 66 · see citing works

Tumour necrosis factor‐induced gene expression in human marrow stroma: clues to the pathophysiology of MDS?

Stirewalt, D. L., Mhyre, A. J., Marcondes, M., Pogosova‐Agadjanyan, E. L., Abbasi, N., Radich, J. P., & Deeg, H. J. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06923.x · Cited by 52 · see citing works

A critical role for DAP10 and DAP12 in CD8+ T cell–mediated tissue damage in large granular lymphocyte leukemia

Chen, X., Bai, F., Sokol, L., Zhou, J., Ren, A., Painter, J. S., Liu, J., Sallman, D. A., Chen, Y. A., Yoder, J. A., et al. (2008) · Blood · doi:10.1182/blood-2008-07-168245 · Cited by 48 · see citing works

Disordered Hematopoiesis and Myelodysplasia in the Elderly

Rothstein, G. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.51.3s.3.x · Cited by 48 · see citing works

Innate Immune Signaling in the Myelodysplastic Syndromes

Starczynowski, D. T., & Karsan, A. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.02.008 · Cited by 47 · see citing works

Molecular Pathogenesis of MDS.

Look, A. (2005) · Hematology. American Society of Hematology. Education Program · doi:10.1182/asheducation-2005.1.156 · Cited by 47 · see citing works

Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid

Estey, E. H., Koller, C. A., Tsimberidou, A. M., O'Brien, S. M., Beran, M., Cortes, J. E., Tírado-Gómez, M., Lopez‐Berestein, G., & Kantarjian, H. M. (2005) · Blood · doi:10.1182/blood-2004-09-3437 · Cited by 27 · see citing works

Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q

Starczynowski, D. T., & Karsan, A. (2010) · Cell Cycle · doi:10.4161/cc.9.5.11156 · Cited by 23 · see citing works

Inflammaging-Associated Metabolic Alterations Foster Development of the MDS Genotype

Wei, S., Eksioglu, E. A., Chen, X., et al. (2015) · Blood · doi:10.1182/blood.v126.23.144.144 · Cited by 7 · see citing works

Myelodysplastic syndromes and bone marrow microenvironment

Porta, M. G. D. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.07.035 · Cited by 5 · see citing works

Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

Silvin, A., Chapuis, N., Dunsmore, G., Goubet, A.-G., Dubuisson, A., Derosa, L., Almire, C., Hénon, C., Kosmider, O., Droin, N., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.002 · Cited by 834 · see citing works

The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes

Sallman, D. A., & List, A. (2019) · Blood · doi:10.1182/blood-2018-10-844654 · Cited by 273 · see citing works

Chronic immune response dysregulation in MDS pathogenesis

Barreyro, L., Chlon, T. M., & Starczynowski, D. T. (2018) · Blood · doi:10.1182/blood-2018-03-784116 · Cited by 226 · see citing works

Nutrient Zinc at the Host–Pathogen Interface

Lonergan, Z. R., & Skaar, E. P. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2019.06.010 · Cited by 129 · see citing works

Inflammatory bone marrow microenvironment

Leimkühler, N. B., & Schneider, R. K. (2019) · Hematology · doi:10.1182/hematology.2019000045 · Cited by 82 · see citing works

Bone marrow morphology during haematopoietic stem cell mobilisation with cyclophosphamide in mice.

Karbicka, A., Marchlewicz, M., Wiszniewska, B., et al. (2003) · PubMed · Cited by 6 · see citing works

Bone marrow morphology during haematopoietic stem cell mobilization with G-CSF in mice.

Barcew, K., Kacińska, E., Marchlewicz, M., et al. (2004) · PubMed · Cited by 4 · see citing works

[The role of the hemopoiesis-inducing microenvironment in the postradiation regeneration of hemopoiesis].

Vi, A., Дыгай, А. М., Vp, S., et al. (1994) · PubMed · Cited by 1 · see citing works

Aberrant myeloid marker expression in precursor B-cell and T-cell leukemias

Suggs, J. L., Cruse, J. M., & Lewis, R. E. (2007) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2007.08.012 · Cited by 55 · see citing works

Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment

Naveiras, O., Nardi, V., Wenzel, P. L., Hauschka, P. V., Fahey, F., & Daley, G. Q. (2009) · Nature · doi:10.1038/nature08099 · Cited by 1,129 · see citing works